Tradipitant - Vanda Pharmaceuticals
Alternative Names: LY-686017; VLY 686Latest Information Update: 18 Mar 2025
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
- Class Anti-inflammatories; Antipruritics; Antivirals; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Gastrokinetics; Pyridines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Atopic dermatitis; COVID 2019 infections; Gastroparesis; Motion sickness
- Phase II Dyspepsia; Nausea and vomiting; Pruritus
- Discontinued Alcoholism; Social phobia
Most Recent Events
- 25 Feb 2025 Phase-II clinical trials in Nausea and vomiting (In volunteers) in USA (PO) (NCT06804603)
- 06 Feb 2025 Vanda Pharmaceuticals plans a phase II trial for Obesity in (Country) (Ref), (NCT ref)
- 27 Jan 2025 Vanda Pharmaceuticals accepts US FDA's offer for a hearing on NDA for Tradipitant in Gastroparesis